Derniers articles

Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort)

Highlights•First real-world multicentre data on adjuvant capecitabine in resected biliary tract cancer.•Capecitabine...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : JHEP Reports

Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol

AbstractIntroductionCurative-intent resection of colorectal cancer (CRC) liver metastasis (CRLM), combined with...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ Open

Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors

Highlights•Dual CTLA-4/PD-1 was associated with improved progression-free survival and overall survival versus...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clinical Colorectal Cancers and Other Gastrointestinal Malignancies

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/ BRAF wild-type metastatic colorectal cancer

AbstractManaging unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy,...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : Signal Transduction and Targeted Therapy

Surgical modality non-inferiority testing with an intensification of adjuvant treatments: a missed opportunity

Surgery of early cervical cancer has deeply evolved in the last 30 years. A de-escalation provided a similar survival...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : International Journal of Gynecological Cancer

Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO

Highlights•This study reports the largest evaluation of targeted therapies in metastatic SBA.•Antiangiogenics plus...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : European Journal of Cancer

Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France.

Abstract ObjectivesThis study aimed to fill the data gap regarding the prevalence of germline...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Aurélia MEURISSE
Nom de la revue : Cancers

Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer.

Abstract Cisplatin-based concurrent chemoradiation (CRT) remains the standard treatment for locally advanced head...

Posté par : Mr. Cyril BOISSON, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Oncoimmunology

Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.

Abstract Antiphospholipid syndrome (APS) is an autoimmune condition with thrombotic and/or obstetric manifestations...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Thrombosis and Haemostasis

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process

Abstract

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Radiotherapy and Oncology

Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.

Abstract Patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors or antiangiogenic...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Nature Medicine

Cancer du sein : un exemple d’évolution des pratiques intégrant les spécificités liées à l’âge. À propos de l’étude ASTER 70s

Abstract According to figures from GLOBOCAN and the European Cancer Information System, nearly 40% of breast cancers...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : La Revue du Praticien

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

AbstractContext and aimsEverolimus was approved in 2012 for the treatment of advanced hormone-receptor-positive,...

Posté par : Mr. Cyril BOISSON, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Breast Cancer Research

Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)

AbstractBackgroundMicrosatellite instability (MSI) or mismatch‑repair deficiency (dMMR) defines a biologically...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Digestive and Liver Disease

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial

SummaryBackgroundThe standard of care for patients with locally advanced squamous cell anal carcinoma (SCAC) is...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Lancet Oncology

Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study

AbstractBackground: In RAS wild-type (WT) metastatic colorectal cancer (mCRC), preliminary data have suggested that...

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Journal of the National Cancer Institute

Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the A GORTEC 2014-04 “OMET” Randomized Phase 2 Trial

AbstractPurposeThe OMET GORTEC 2014-04 trial showed prolonged survival with multisite Stereotactic Ablative Body...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : International Journal of Radiation Oncology . Biology . Physics

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials

AbstractPurposeImmunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Journal of Clinical Oncology

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials

AbstractPurposeThe objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Journal of Clinical Oncology

Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer

AbstractPurposeThe randomized phase II GORTEC 2014–04 and French Head and Neck Intergroup study showed deeper...

Posté par : Mr. Antoine FALCOZ, Mme. Aurélia MEURISSE
Nom de la revue : Radiotherapy and Oncology